Literature DB >> 2084668

Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem.

K G Kerr, P M Hawkey, J A Child, D R Norfolk, A W Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2084668      PMCID： PMC2429775          DOI： 10.1136/pgmj.66.782.1090

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

1.  Imipenem-cilastatin as initial therapy for febrile cancer patients.

Authors:  G P Bodey; M E Alvarez; P G Jones; K V Rolston; L Steelhammer; V Fainstein
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature.

Authors:  J J Zuravleff; V L Yu
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

3.  Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections.

Authors:  F Diaz-Mitoma; G K Harding; T J Louie; M Thomson; M James; A R Ronald
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

4.  Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum.

Authors:  R R Muder; V L Yu; J S Dummer; C Vinson; R M Lumish
Journal:  Arch Intern Med       Date:  1987-09

Review 5.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790
  5 in total
  2 in total

Review 1.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 2.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.